176 assets in HER2 Positive Breast Carcinoma

Therapeutic assets addressing HER2 Positive Breast Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cetuximab HER2 Positive Breast Carcinoma	Sun Yat-sen University	P2	B (56)
hb1801 HER2 Positive Breast Carcinoma	Shanghai JMT-Bio Inc.	P3	B (56)
ibi354 HER2 Positive Breast Carcinoma	Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.	P3	B (56)
Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Erbb2 (Receptor Tyrosine-Protein Kinase Erbb-2, Epidermal Growth Factor Receptor 2, Egfr2, Her2, Her-2, P185C-Erbb2, Neu, Cd340)], Humanized Monoclonal Antibody, Conjugated At Glutaminyl Residues To Monomethylauristatin E (Mmae), With A Ratio Of 1 To 2, Via A Cleavable Linker HER2 Positive Breast Carcinoma	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	P3	B (56)
Jskn003 HER2 Positive Breast Carcinoma	Shanghai JMT-Bio Inc.	P3	B (56)
Irinotecan HER2 Positive Breast Carcinoma	Sun Yat-sen University	P2	CCC (55)
Pembrolizumab HER2 Positive Breast Carcinoma	M.D. Anderson Cancer Center	P2	CCC (55)
arx788 HER2 Positive Breast Carcinoma	Henan Cancer Hospital	P2/3	CCC (54)
Carvedilol HER2 Positive Breast Carcinoma	Washington University School of Medicine	P2	CCC (53)
Colesevelam HER2 Positive Breast Carcinoma	Spanish Breast Cancer Research Group	P2	CCC (53)
Disitamab HER2 Positive Breast Carcinoma	Zhejiang Cancer Hospital	P2	CCC (53)
Etoposide HER2 Positive Breast Carcinoma	Institut Curie	P2	CCC (53)
Hyaluronidase Oysk HER2 Positive Breast Carcinoma	Adrienne G. Waks	P2	CCC (53)
S-1 HER2 Positive Breast Carcinoma	Aiping Zhou	P2	CCC (53)
Sacituzumab Tirumotecan HER2 Positive Breast Carcinoma	Fudan University	P2	CCC (53)
Talazoparib HER2 Positive Breast Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
tqb2102 HER2 Positive Breast Carcinoma	Henan Cancer Hospital	P2	CCC (53)
bnt323 HER2 Positive Breast Carcinoma	DualityBio Inc.	P3	CCC (52)
Fam-Trastuzumab Deruxtecan-Nxki HER2 Positive Breast Carcinoma	Memorial Sloan Kettering Cancer Center	P2	CCC (52)
gq1005 HER2 Positive Breast Carcinoma	GeneQuantum Healthcare (Suzhou) Co., Ltd.	P3	CCC (52)
hlx11 HER2 Positive Breast Carcinoma	Shanghai Henlius Biotech	P3	CCC (52)
Olaparib HER2 Positive Breast Carcinoma	Gustave Roussy, Cancer Campus, Grand Paris	P2	CCC (52)
Sysa-1901 (Pertuzumab Biosimilar) HER2 Positive Breast Carcinoma	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	P3	CCC (52)
tqb2101 for HER2 Positive Breast Carcinoma	Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.	P3	CCC (52)
Trastuzumab Duocarmazine HER2 Positive Breast Carcinoma	QuantumLeap Healthcare Collaborative	P2	CCC (52)
Trastuzumab Pamirtecan HER2 Positive Breast Carcinoma	DualityBio Inc.	P3	CCC (52)
Hyaluronidase Zzxf HER2 Positive Breast Carcinoma	Latin American Cooperative Oncology Group	P2	CCC (51)
Trastuzumab Imbotolimod HER2 Positive Breast Carcinoma	Bolt Biotherapeutics, Inc.	P2	CCC (51)
ro7771950 HER2 Positive Breast Carcinoma	Hoffmann-La Roche	P2/3	CCC (50)
Ganetespib HER2 Positive Breast Carcinoma	Memorial Sloan Kettering Cancer Center	P2	CCC (49)
mk-2206 HER2 Positive Breast Carcinoma	National Cancer Institute (NCI)	P2	CCC (49)
Zn-A-1041 HER2 Positive Breast Carcinoma	Suzhou Zanrong Pharma Limited	P1/2	CCC (49)
9mw2821 HER2 Positive Breast Carcinoma	Fudan University	P2	CCC (48)
Aguix HER2 Positive Breast Carcinoma	Brigham and Women's Hospital	P2	CCC (48)
Anti-Pd-L1 Monoclonal Antibody Shr-1316 HER2 Positive Breast Carcinoma	Fudan University	P2	CCC (48)
Asciminib HER2 Positive Breast Carcinoma	Duke University	P1/2	CCC (48)
Benmelstobart HER2 Positive Breast Carcinoma	Fudan University	P2	CCC (48)
Catequentinib HER2 Positive Breast Carcinoma	Fudan University	P2	CCC (48)
Chimeric Antigen Receptor Modified T Cells Infusion HER2 Positive Breast Carcinoma	National University Hospital, Singapore	P1/2	CCC (48)
Dan-222 HER2 Positive Breast Carcinoma	QuantumLeap Healthcare Collaborative	P2	CCC (48)
Datopotamab Deruxtecan HER2 Positive Breast Carcinoma	QuantumLeap Healthcare Collaborative	P2	CCC (48)
Dostarlimab HER2 Positive Breast Carcinoma	QuantumLeap Healthcare Collaborative	P2	CCC (48)
Durvalumab HER2 Positive Breast Carcinoma	Filipa Lynce, MD	P2	CCC (48)
Edotreotide HER2 Positive Breast Carcinoma	MedSIR	P2	CCC (48)
Empagliflozin HER2 Positive Breast Carcinoma	Washington University School of Medicine	P2	CCC (48)
Encequidar HER2 Positive Breast Carcinoma	QuantumLeap Healthcare Collaborative	P2	CCC (48)
Eribulin Monomethanesulfonate HER2 Positive Breast Carcinoma	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	P2	CCC (48)
Famitinib HER2 Positive Breast Carcinoma	Fudan University	P2	CCC (48)
Fianlimab HER2 Positive Breast Carcinoma	QuantumLeap Healthcare Collaborative	P2	CCC (48)
Fluzoparib HER2 Positive Breast Carcinoma	Fudan University	P2	CCC (48)

Showing 51 to 100 of 176 assets

PreviousPage 2 of 4Next